SUSTAINED IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE OUTCOMES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH CONTINUED MIRIKIZUMAB TREATMENT IN PHASE 3 LUCENT-3 STUDY

被引：0
|
作者：
Sands, B. E. [1 ]
Feagan, B. G. [2 ]
Armuzzi, A. [3 ,4 ]
Mcginnis, K. [5 ]
Lynch, K. [6 ]
Gibble, Hunter T. [5 ]
Johns, J. [5 ]
Siegel, C. A. [7 ]
Jairath, V. [8 ]
Asaro, J. [9 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY USA
[2] Alimentiv Inc, London, ON, Canada
[3] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy
[4] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] Univ Utah, Div Gastroenterol & Hepatol, Sch Med, Salt Lake City, UT USA
[7] Dartmouth Hitchcock Med Ctr, Sect Gastroenterol & Hepatol, Lebanon, NH USA
[8] Western Univ, London, ON, Canada
[9] Eli Lilly Italia SpA, Sesto Fiorentino, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OC.07.7
引用
收藏
页码：S166 / S166
页数：1
相关论文
共 50 条
  • [1] Sustained Improvement in Inflammatory Bowel Disease Questionnaire Outcomes in Moderately to Severely Active Ulcerative Colitis With Continued Mirikizumab Treatment in Phase 3 LUCENT-3 Study
    Sands, Bruce E.
    Feagan, Brian G.
    Armuzzi, Alessandro
    McGinnis, Kim
    Lynch, Keisa
    Gibble, Theresa Hunter
    Johns, Jordan
    Siegel, Corey A.
    Jairath, Vipul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S813
  • [2] Mirikizumab Demonstrates Sustained Improvement in Fatigue in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Regueiro, Miguel
    Gibble, Theresa Hunter
    Bleakman, Alison Potts
    Li, Xingyuan
    Morris, Nathan
    Eastman, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S518 - S519
  • [3] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023, : 1479 - 1491
  • [4] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023,
  • [5] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
    Sandborn, W. J.
    Sands, B.
    Kobayashi, T.
    Tuttle, J.
    Schmitz, J.
    Durante, M.
    Higgs, R.
    Canavan, J. B.
    Siegel, R.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60
  • [6] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
    Andrews, J. M.
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
  • [7] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
  • [8] Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study
    Hart, A.
    Blumenstein, I
    Kobayashi, T.
    Chaparro, M.
    Fantini, M. C.
    Fumery, M.
    Keohane, A.
    Dhesi, E.
    Tian, T.
    Redondo, I
    Barnes, E. L.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1452 - i1454
  • [9] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
    Dubinsky, Marla C.
    Irving, Peter M.
    Li, Xingyuan
    Howaldt, Stefanie
    Pokrotnieks, Juris
    Krueger, Kathryn A.
    Laskowski, Janelle
    Lissoos, Trevor
    Milata, Joe
    Morris, Nathan
    Arora, Vipin
    Milch, Catherine
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394
  • [10] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Laiyi Chua
    Stuart Friedrich
    Xin Cindy Zhang
    Clinical Pharmacokinetics, 2023, 62 (10) : 1479 - 1491
12345